Table 1.
Current clinical experience with treatment of non-M infectionsa
| Virus group | No. of treated patients | Country(ies) of monitoring | Treatment line(s) usedb | Reference |
|---|---|---|---|---|
| HIV-O | 22 | France | 3 NRTI (n = 2) | 43 |
| 2 NRTI + PI (n = 18) | ||||
| 2 NRTI + PI + RAL (n = 1) | ||||
| 2 NRTI + RAL (n = 1) | ||||
| 12 | France | Multiple lines including NRTI ± NNRTI ± PI ± T20 + RALc | 106 | |
| 9 | France | Multiple lines including NRTI ± NNRTI ± PI ± RAL + T20c | 108 | |
| 6 | Spain and England | Multiple lines including 2 NRTI + PIc | 113 | |
| 2 | Belgium and The Netherlands | Multiple lines including 2 NRTI + PI (d4T + 3TC + IDVc) | 112 | |
| 1 | Cameroon | Multiple lines including 2 NRTI + PI + RAL (TDF + 3TC + DRV-r + RALc) | 107 | |
| 1 | France | 2 NRTI + PI (AZT + 3TC + LPV-rc) | 73 | |
| 1 | Spain | Multiple lines including 2 NRTI + PI + RAL (ddI + FTC + DRV-r + RALc) | 105 | |
| 1 | Spain | Multiple lines including NRTI + PI + T20 (d4T + 3TC + TDF + TPV-r + T20c) | 110 | |
| HIV-N | 1 | Cameroon | 2 NRTI + NNRTI (3TC + d4T + NVPc) | 47 |
| 1 | France | 2 NRTI + PI + RAL + MVC (TDF + FTC + DRV-r + RAL + MVCc) | 28 | |
| HIV-P | 1 | France | 2 NRTI + PI (ABC + 3TC + LPV-rc) | Our unpublished data |
As the clinical course of non-M infections appears to be similar to that of HIV-M infection, the same criteria for starting treatment are currently used. Data on the treatment response in vivo are extremely sparse. Presented is a summary of current clinical experiences with treatment of infections with HIV-O, -N, and -P.
The drugs are as follows: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; DRV, darunavir; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; MVC, maraviroc; NVP, nevirapine; r, ritonavir; RAL, raltegravir; T20, enfuvirtide; TDF, tenofovir; TPV, tipranavir. The drug classes are as follows: NRTIs, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.
Late-known treatment at the time of publication.